Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04983056 |
Other study ID # |
FZBKSMP35 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 1, 2010 |
Est. completion date |
July 2, 2021 |
Study information
Verified date |
July 2021 |
Source |
Centre Hospitalier Universitaire Ibn Rochd |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Case series with retrospective data collection of patients treated for Fournier's gangrene
between January 2010 and March 2017. The main etiologies, risk factors, postoperative
complications outcomes and long term follow up results were analyzed.
Description:
Eight four (84) patients were recruited. The average age of our patients was 49 years (with
limits of 20 to 76), the male gender dominates our series (83.33%) with a sex ratio of 5M /
1W, the most frequently found risk factor was diabetes mellitus (37%). The most common
etiology was anal abscesses (32%). The average time to consultation was 8 days (limits ranges
from 3 to 30 days). All patients were admitted at a necrosis stage (100%). Anemia was
identified in 85% of cases. The low platelets were noticed in 44.03% of cases.
Hypoalbuminemia was found in 93% of cases. All patients (100%) benefited resuscitation
initially and antibiotic therapy on their admission. They received emergency surgical
debridement with a cleansing stoma. The average length of hospital stay was 13 days and
complications occurred in 33% of cases. The mortality rate was 7.14%. then we conclude that
Fournier's gangrene is a medico-surgical emergency with a high morbidity and mortality rate.
Early diagnosis as well as antibiotic therapy and the quality of debridement save the
patients.